A Phase 3 Study Comparing Oral Ixazomib Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Participants With Relapsed and/or Refractory Multiple Myeloma

Dana Farber Cancer Institute, Boston

Hackensack University Medical Center, Hackensack

Columbia University Medical Center, New York

Roswell Park Cancer Institute, Buffalo

Scranton Hematology Oncology, Scranton

Blood and Cancer Clinic, Fayetteville

MUSC Hollings Cancer Center, Charleston

Northwest Georgia Oncology Center, Marietta

University of Florida, Gainesville

Cancer & Blood Disease Center, Lecanto

Medical College of Wisconsin, Milwaukee

Mayo Clinic, Rochester

John H. Stroger, Jr. Hospital of Cook County, Chicago

University of Arkansas Medical Sciences, Little Rock

Pacific Cancer Medical Center Inc, Anaheim

West Contra Costa Healthcare District, Berkeley

Fred Hutchinson Cancer Research, Seattle

West Virginia University Hospitals and Clinic, Morgantown

Tom Baker Cancer Centre, Calgary

Cross Cancer Institute, Edmonton

Vancouver General Hospital, Vancouver

Saint John Regional Hospital, Saint John

CHUM Notre-Dame Hospital, Montreal

MUHC Glen Site Cedars Cancer Centre, Montreal